Cargando…
Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort
BACKGROUND: FACEmemory® is the first computerized, self-administered verbal episodic memory test with voice recognition. It can be conducted under minimal supervision and contains an automatic scoring system to avoid administrator errors. Moreover, it is suitable for discriminating between cognitive...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933921/ https://www.ncbi.nlm.nih.gov/pubmed/35303916 http://dx.doi.org/10.1186/s13195-022-00988-8 |
_version_ | 1784671762141675520 |
---|---|
author | Alegret, Montserrat Sotolongo-Grau, Oscar de Antonio, Ester Esteban Pérez-Cordón, Alba Orellana, Adelina Espinosa, Ana Gil, Silvia Jiménez, Daniel Ortega, Gemma Sanabria, Angela Roberto, Natalia Hernández, Isabel Rosende-Roca, Maitee Tartari, Juan Pablo Alarcon-Martin, Emilio de Rojas, Itziar Montrreal, Laura Morató, Xavier Cano, Amanda Rentz, Dorene M. Tárraga, Lluís Ruiz, Agustín Valero, Sergi Marquié, Marta Boada, Mercè |
author_facet | Alegret, Montserrat Sotolongo-Grau, Oscar de Antonio, Ester Esteban Pérez-Cordón, Alba Orellana, Adelina Espinosa, Ana Gil, Silvia Jiménez, Daniel Ortega, Gemma Sanabria, Angela Roberto, Natalia Hernández, Isabel Rosende-Roca, Maitee Tartari, Juan Pablo Alarcon-Martin, Emilio de Rojas, Itziar Montrreal, Laura Morató, Xavier Cano, Amanda Rentz, Dorene M. Tárraga, Lluís Ruiz, Agustín Valero, Sergi Marquié, Marta Boada, Mercè |
author_sort | Alegret, Montserrat |
collection | PubMed |
description | BACKGROUND: FACEmemory® is the first computerized, self-administered verbal episodic memory test with voice recognition. It can be conducted under minimal supervision and contains an automatic scoring system to avoid administrator errors. Moreover, it is suitable for discriminating between cognitively healthy and amnestic mild cognitive impairment (MCI) individuals, and it is associated with Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers. This study aimed to determine whether FACEmemory scoring is related to performance on classical memory tests and to AD biomarkers of brain magnetic resonance imaging (MRI) and CSF in patients with early-onset MCI (EOMCI). METHODS: Ninety-four patients with EOMCI from the BIOFACE study completed FACEmemory, classical memory tests (the Spanish version of the Word Free and Cued Selective Reminding Test -FCSRT-, the Word List from the Wechsler Memory Scale, third edition, and the Spanish version of the Rey–Osterrieth Complex Figure Test), and a brain MRI. Eighty-two individuals also underwent a lumbar puncture. RESULTS: FACEmemory scoring was moderately correlated with FCSRT scoring. With regard to neuroimaging MRI results, worse execution on FACEmemory was associated with lower cortical volume in the right prefrontal and inferior parietal areas, along with the left temporal and associative occipital areas. Moreover, the total FACEmemory score correlated with CSF AD biomarkers (Aβ1-42/Aβ1-40 ratio, p181-tau, and Aβ1-42/p181-tau ratio). When performance on FACEmemory was compared among the ATN classification groups, significant differences between the AD group and normal and SNAP groups were found. CONCLUSIONS: FACEmemory is a promising tool for detecting memory deficits sensitive to early-onset AD, but it also allows the detection of memory-impaired cases due to other etiologies. Our findings suggest that FACEmemory scoring can detect the AD endophenotype and that it is also associated with AD-related changes in MRI and CSF in patients with EOMCI. The computerized FACEmemory tool might be an opportunity to facilitate early detection of MCI in younger people than 65, who have a growing interest in new technologies. |
format | Online Article Text |
id | pubmed-8933921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89339212022-03-23 Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort Alegret, Montserrat Sotolongo-Grau, Oscar de Antonio, Ester Esteban Pérez-Cordón, Alba Orellana, Adelina Espinosa, Ana Gil, Silvia Jiménez, Daniel Ortega, Gemma Sanabria, Angela Roberto, Natalia Hernández, Isabel Rosende-Roca, Maitee Tartari, Juan Pablo Alarcon-Martin, Emilio de Rojas, Itziar Montrreal, Laura Morató, Xavier Cano, Amanda Rentz, Dorene M. Tárraga, Lluís Ruiz, Agustín Valero, Sergi Marquié, Marta Boada, Mercè Alzheimers Res Ther Research BACKGROUND: FACEmemory® is the first computerized, self-administered verbal episodic memory test with voice recognition. It can be conducted under minimal supervision and contains an automatic scoring system to avoid administrator errors. Moreover, it is suitable for discriminating between cognitively healthy and amnestic mild cognitive impairment (MCI) individuals, and it is associated with Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers. This study aimed to determine whether FACEmemory scoring is related to performance on classical memory tests and to AD biomarkers of brain magnetic resonance imaging (MRI) and CSF in patients with early-onset MCI (EOMCI). METHODS: Ninety-four patients with EOMCI from the BIOFACE study completed FACEmemory, classical memory tests (the Spanish version of the Word Free and Cued Selective Reminding Test -FCSRT-, the Word List from the Wechsler Memory Scale, third edition, and the Spanish version of the Rey–Osterrieth Complex Figure Test), and a brain MRI. Eighty-two individuals also underwent a lumbar puncture. RESULTS: FACEmemory scoring was moderately correlated with FCSRT scoring. With regard to neuroimaging MRI results, worse execution on FACEmemory was associated with lower cortical volume in the right prefrontal and inferior parietal areas, along with the left temporal and associative occipital areas. Moreover, the total FACEmemory score correlated with CSF AD biomarkers (Aβ1-42/Aβ1-40 ratio, p181-tau, and Aβ1-42/p181-tau ratio). When performance on FACEmemory was compared among the ATN classification groups, significant differences between the AD group and normal and SNAP groups were found. CONCLUSIONS: FACEmemory is a promising tool for detecting memory deficits sensitive to early-onset AD, but it also allows the detection of memory-impaired cases due to other etiologies. Our findings suggest that FACEmemory scoring can detect the AD endophenotype and that it is also associated with AD-related changes in MRI and CSF in patients with EOMCI. The computerized FACEmemory tool might be an opportunity to facilitate early detection of MCI in younger people than 65, who have a growing interest in new technologies. BioMed Central 2022-03-18 /pmc/articles/PMC8933921/ /pubmed/35303916 http://dx.doi.org/10.1186/s13195-022-00988-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Alegret, Montserrat Sotolongo-Grau, Oscar de Antonio, Ester Esteban Pérez-Cordón, Alba Orellana, Adelina Espinosa, Ana Gil, Silvia Jiménez, Daniel Ortega, Gemma Sanabria, Angela Roberto, Natalia Hernández, Isabel Rosende-Roca, Maitee Tartari, Juan Pablo Alarcon-Martin, Emilio de Rojas, Itziar Montrreal, Laura Morató, Xavier Cano, Amanda Rentz, Dorene M. Tárraga, Lluís Ruiz, Agustín Valero, Sergi Marquié, Marta Boada, Mercè Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort |
title | Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort |
title_full | Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort |
title_fullStr | Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort |
title_full_unstemmed | Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort |
title_short | Automatized FACEmemory® scoring is related to Alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort |
title_sort | automatized facememory® scoring is related to alzheimer’s disease phenotype and biomarkers in early-onset mild cognitive impairment: the bioface cohort |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933921/ https://www.ncbi.nlm.nih.gov/pubmed/35303916 http://dx.doi.org/10.1186/s13195-022-00988-8 |
work_keys_str_mv | AT alegretmontserrat automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT sotolongograuoscar automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT deantonioesteresteban automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT perezcordonalba automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT orellanaadelina automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT espinosaana automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT gilsilvia automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT jimenezdaniel automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT ortegagemma automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT sanabriaangela automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT robertonatalia automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT hernandezisabel automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT rosenderocamaitee automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT tartarijuanpablo automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT alarconmartinemilio automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT derojasitziar automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT montrreallaura automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT moratoxavier automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT canoamanda automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT rentzdorenem automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT tarragalluis automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT ruizagustin automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT valerosergi automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT marquiemarta automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort AT boadamerce automatizedfacememoryscoringisrelatedtoalzheimersdiseasephenotypeandbiomarkersinearlyonsetmildcognitiveimpairmentthebiofacecohort |